Sales grew 6% and EBITDA rose 14% year-over-year in H1 2026, driven by strong specialty chemicals demand and improved margins. New production capacity and a EUR 100 million financing agreement support continued growth, with the outlook for 2026 confirmed.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.